Are you Dr. Martin?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 46 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
607 Garfield St
Tupelo, MS 38801Phone+1 662-840-5200Fax+1 662-840-8216
Summary
- Dr. Sherry Martin, MD is an endocrinologist in Tupelo, Mississippi. She is currently licensed to practice medicine in Mississippi.
Education & Training
Ochsner Clinic FoundationFellowship, Endocrinology, Diabetes, and Metabolism, 1990 - 1992
University of North Carolina HospitalsFellowship, Clinical Pharmacology, 1985 - 1986- University of North Carolina HospitalsResidency, Internal Medicine, 1982 - 1985
University of Mississippi School of MedicineClass of 1982
Certifications & Licensure
MS State Medical License 1983 - 2020
Publications & Presentations
PubMed
- 12 citationsComparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a p...Richard Arakaki, T. C. Blevins, J. K. Wise, D. R. Liljenquist, Honghua Jiang
Diabetes, Obesity & Metabolism. 2014-06-01 - 28 citationsThe DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) Trial Comparing the durability of lispro mix 75/25 and glargineJohn B. Buse, Bruce H. R. Wolffenbuttel, William H. Herman, Stephen Hippler, Sherry Martin
Diabetes Care. 2011-02-01 - 33 citationsDulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 Trials.Paolo Pozzilli, Richard David Leslie, Anne L. Peters, Raffaella Buzzetti, Sudha S. Shankar
Diabetes, Obesity & Metabolism. 2018-06-01
Press Mentions
Dulaglutide Receives FDA Approval for Reducing MACE in Type 2 DiabeticsFebruary 24th, 2020
Empagliflozin Better for Patients at High Cardiovascular RiskNovember 21st, 2019
Powder-Delivery Device Approved for First and Only Nasally Administered GlucagonJuly 30th, 2019- Join now to see all
